Vector production in an academic environment

A tool to assess production costs

Aaron Boeke, Patrick Doumas, Lilith Reeves, Kyle McClurg, Daniela Bischof, Lina Sego, Alisha Auberry, Mohan Tatikonda, Kenneth Cornetta

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Generating gene and cell therapy products under good manufacturing practices is a complex process. When determining the cost of these products, researchers must consider the large number of supplies used for manufacturing and the personnel and facility costs to generate vector and maintain a cleanroom facility. To facilitate cost estimates, the Indiana University Vector Production Facility teamed with the Indiana University Kelley School of Business to develop a costing tool that, in turn, provides pricing. The tool is designed in Microsoft Excel and is customizable to meet the needs of other core facilities. It is available from the National Gene Vector Biorepository. The tool allows cost determinations using three different costing methods and was developed in an effort to meet the A21 circular requirements for U.S. core facilities performing work for federally funded projects. The costing tool analysis reveals that the cost of vector production does not have a linear relationship with batch size. For example, increasing the production from 9 to18 liters of a retroviral vector product increases total costs a modest 1.2-fold rather than doubling in total cost. The analysis discussed in this article will help core facilities and investigators plan a cost-effective strategy for gene and cell therapy production.

Original languageEnglish
Pages (from-to)49-57
Number of pages9
JournalHuman gene therapy methods
Volume24
Issue number1
DOIs
StatePublished - Feb 1 2013

Fingerprint

Costs and Cost Analysis
Cell- and Tissue-Based Therapy
Genetic Therapy
Research Personnel
Genes

ASJC Scopus subject areas

  • Molecular Medicine
  • Applied Microbiology and Biotechnology
  • Genetics(clinical)
  • Genetics
  • Pharmacology

Cite this

Vector production in an academic environment : A tool to assess production costs. / Boeke, Aaron; Doumas, Patrick; Reeves, Lilith; McClurg, Kyle; Bischof, Daniela; Sego, Lina; Auberry, Alisha; Tatikonda, Mohan; Cornetta, Kenneth.

In: Human gene therapy methods, Vol. 24, No. 1, 01.02.2013, p. 49-57.

Research output: Contribution to journalArticle

Boeke, A, Doumas, P, Reeves, L, McClurg, K, Bischof, D, Sego, L, Auberry, A, Tatikonda, M & Cornetta, K 2013, 'Vector production in an academic environment: A tool to assess production costs', Human gene therapy methods, vol. 24, no. 1, pp. 49-57. https://doi.org/10.1089/hgtb.2012.213
Boeke, Aaron ; Doumas, Patrick ; Reeves, Lilith ; McClurg, Kyle ; Bischof, Daniela ; Sego, Lina ; Auberry, Alisha ; Tatikonda, Mohan ; Cornetta, Kenneth. / Vector production in an academic environment : A tool to assess production costs. In: Human gene therapy methods. 2013 ; Vol. 24, No. 1. pp. 49-57.
@article{cd345929219b47f88fac51eb91e8de79,
title = "Vector production in an academic environment: A tool to assess production costs",
abstract = "Generating gene and cell therapy products under good manufacturing practices is a complex process. When determining the cost of these products, researchers must consider the large number of supplies used for manufacturing and the personnel and facility costs to generate vector and maintain a cleanroom facility. To facilitate cost estimates, the Indiana University Vector Production Facility teamed with the Indiana University Kelley School of Business to develop a costing tool that, in turn, provides pricing. The tool is designed in Microsoft Excel and is customizable to meet the needs of other core facilities. It is available from the National Gene Vector Biorepository. The tool allows cost determinations using three different costing methods and was developed in an effort to meet the A21 circular requirements for U.S. core facilities performing work for federally funded projects. The costing tool analysis reveals that the cost of vector production does not have a linear relationship with batch size. For example, increasing the production from 9 to18 liters of a retroviral vector product increases total costs a modest 1.2-fold rather than doubling in total cost. The analysis discussed in this article will help core facilities and investigators plan a cost-effective strategy for gene and cell therapy production.",
author = "Aaron Boeke and Patrick Doumas and Lilith Reeves and Kyle McClurg and Daniela Bischof and Lina Sego and Alisha Auberry and Mohan Tatikonda and Kenneth Cornetta",
year = "2013",
month = "2",
day = "1",
doi = "10.1089/hgtb.2012.213",
language = "English",
volume = "24",
pages = "49--57",
journal = "Human gene therapy methods",
issn = "1946-6536",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Vector production in an academic environment

T2 - A tool to assess production costs

AU - Boeke, Aaron

AU - Doumas, Patrick

AU - Reeves, Lilith

AU - McClurg, Kyle

AU - Bischof, Daniela

AU - Sego, Lina

AU - Auberry, Alisha

AU - Tatikonda, Mohan

AU - Cornetta, Kenneth

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Generating gene and cell therapy products under good manufacturing practices is a complex process. When determining the cost of these products, researchers must consider the large number of supplies used for manufacturing and the personnel and facility costs to generate vector and maintain a cleanroom facility. To facilitate cost estimates, the Indiana University Vector Production Facility teamed with the Indiana University Kelley School of Business to develop a costing tool that, in turn, provides pricing. The tool is designed in Microsoft Excel and is customizable to meet the needs of other core facilities. It is available from the National Gene Vector Biorepository. The tool allows cost determinations using three different costing methods and was developed in an effort to meet the A21 circular requirements for U.S. core facilities performing work for federally funded projects. The costing tool analysis reveals that the cost of vector production does not have a linear relationship with batch size. For example, increasing the production from 9 to18 liters of a retroviral vector product increases total costs a modest 1.2-fold rather than doubling in total cost. The analysis discussed in this article will help core facilities and investigators plan a cost-effective strategy for gene and cell therapy production.

AB - Generating gene and cell therapy products under good manufacturing practices is a complex process. When determining the cost of these products, researchers must consider the large number of supplies used for manufacturing and the personnel and facility costs to generate vector and maintain a cleanroom facility. To facilitate cost estimates, the Indiana University Vector Production Facility teamed with the Indiana University Kelley School of Business to develop a costing tool that, in turn, provides pricing. The tool is designed in Microsoft Excel and is customizable to meet the needs of other core facilities. It is available from the National Gene Vector Biorepository. The tool allows cost determinations using three different costing methods and was developed in an effort to meet the A21 circular requirements for U.S. core facilities performing work for federally funded projects. The costing tool analysis reveals that the cost of vector production does not have a linear relationship with batch size. For example, increasing the production from 9 to18 liters of a retroviral vector product increases total costs a modest 1.2-fold rather than doubling in total cost. The analysis discussed in this article will help core facilities and investigators plan a cost-effective strategy for gene and cell therapy production.

UR - http://www.scopus.com/inward/record.url?scp=84878267594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878267594&partnerID=8YFLogxK

U2 - 10.1089/hgtb.2012.213

DO - 10.1089/hgtb.2012.213

M3 - Article

VL - 24

SP - 49

EP - 57

JO - Human gene therapy methods

JF - Human gene therapy methods

SN - 1946-6536

IS - 1

ER -